Istvan Galo will assume the role of chief commercial officer at Geistlich, a global leader in regenerative dentistry, on 1 Feb 2026. In this position, he will oversee the company’s global sales organisation and support its expansion into new market regions, customer segments and sales channels.
Born in Hungary, Galo brings extensive management experience from the dental and consumer goods sectors and has been based in Switzerland since 2011. His career includes senior leadership roles at Ivoclar and Electronic Arts (EA), where he most recently held global responsibility for commercialisation, including market launches and marketing strategy.
With Galo’s appointment, Geistlich aims to advance its growth and diversification strategy, with a focus on emerging markets and new customer segments. To address a wide range of clinical and market needs, the company plans to expand its portfolio by 20 new products across more than 40 countries by the end of 2026. This includes new technologies and product variants such as Geistlich Bio-Gide Forte and Geistlich Bio-Oss Flow, as well as the introduction of Geistlich SwissGraft X and Geistlich SwissMembrane X for emerging markets. By 2035, Geistlich aims to further improve quality of life through the delivery of high-quality dental regeneration solutions.
Diego Gabathuler, chief executive officer of Geistlich Pharma, said that the company’s strategy not only strengthens its position in established markets but also expands access to regenerative solutions for additional patient groups worldwide. He added that Galo’s expertise will support Geistlich in pursuing its long-term growth objectives.
